Federation Bio Launches with $50 Million Series A Financing and Expands Team to Pioneer Diverse Microbial Therapies

Oct 06, 2020•almost 5 years ago

Amount Raised

$50 Million

Round Type

series a

San Francisco

Description

Federation Bio, a microbial therapeutics company targeting diseases in which the human microbiome can play a curative role, today announced that it has closed a $50 million Series A financing and expanded its leadership team. Federation Bio is pioneering new approaches for treating intractable diseases by combining an unprecedented number of microbial strains into highly diverse consortia, in some instances optimized with genetically engineered bacteria to enhance the immune system. The company was founded by Michael Fischbach, Ph.D., and Dylan Dodd, M.D., Ph.D., with support from Venrock.

Company Information

Company

Federation Bio

Location

San Francisco, California, United States

About

Federation Bio is pioneering new platforms that target diseases in which the human microbiome can play a curative role. The company's microbial therapy leverages naturally occurring or engineered bacteria along with a diverse community of supportive bacteria to drive engraftment and durable therapeutic responses. This approach has potential in a wide range of human conditions, from metabolic disorders and cholestatic diseases to cancer and autoimmune conditions. Federation Bio's lead program is in secondary hyperoxaluria, a serious renal condition that affects more than 200,000 Americans and for which there are currently no approved therapies. Additional information can be found at www.federation.bio

FundzWatch™ Score

Medium Activity

Buyer Intent Analysis

Get personalized insights on buying likelihood

Funding Insights

Based on industry data

Tech investment trends